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1. INTRODUCTION {#mgg31246-sec-0005}
===============

Cervical cancer is the fourth common gynecological cancer, which causes high cancer‐related deaths among women, especially in developing countries (McGuire, [2016](#mgg31246-bib-0015){ref-type="ref"}). It is estimated that 266,000 deaths and 528,000 new cases occurred globally each year (Ferlay et al., [2015](#mgg31246-bib-0002){ref-type="ref"}). The increasing researches have provided evidence that the human papillomavirus (HPV) is a primary risk factor of cervical cancer. However, most women are temporarily infected with HPV, and only a small portion of them will develop cervical cancer, indicating that other factors also played a crucial role in the development of cervical cancer (Hariri et al., [2011](#mgg31246-bib-0006){ref-type="ref"}). Plenty of epidemiological studies suggested that environment stimulation and individual heritability were associated with the occurrence and development of cervical cancer (Liu, Zhou, Su, & Zhang, [2019](#mgg31246-bib-0013){ref-type="ref"}; Liu, Lyu, Zhang, Sheng, & Tang, [2017](#mgg31246-bib-0014){ref-type="ref"}). Single nucleotide polymorphisms (SNPs) are considered to be correlated with various cancers, such as lung cancer (Zhong et al., [2013](#mgg31246-bib-0026){ref-type="ref"}), breast cancer (Xia et al., [2015](#mgg31246-bib-0021){ref-type="ref"}), gastric cancer (Yuan et al., [2012](#mgg31246-bib-0024){ref-type="ref"}), and cervical cancer (Gao et al., [2019](#mgg31246-bib-0004){ref-type="ref"}). Thus, in order to develop effective personalized medicine, the detection of SNPs is very important for the susceptibility of cervical cancer.

Long noncoding RNAs (lncRNAs) are members of these ncRNA families. They are a type of RNA transcripts with more than 200 nucleotides and no protein‐coding ability. Numerous studies have revealed that lncRNAs are involved in gene function via multiple mechanisms, such as transcriptional regulation, chromatin remodeling, and genetic imprinting (Glusman et al., [2006](#mgg31246-bib-0005){ref-type="ref"}). Moreover, there are increasing studies indicated that lncRNA polymorphism was correlated with various cancer risks (Tang et al., [2017](#mgg31246-bib-0019){ref-type="ref"}). Cancer susceptibility candidate 15 (*CASC15*, OMIM\# 616610) is a highly active lncRNA, also known as LINC00340 (Yin, Zhao, Li, & Yin, [2018](#mgg31246-bib-0023){ref-type="ref"}). Jing et al reported that the high expression of *CASC15* affected the development of gastric cancer (Yao, Tang, Zhu, & Jing, [2017](#mgg31246-bib-0022){ref-type="ref"}). A research consisting of 118 cases and 281 healthy controls confirmed that *CASC15* polymorphisms significantly reduced the risk of neuroblastoma among Chinese children (Zhang et al., [2017](#mgg31246-bib-0025){ref-type="ref"}). Shan et al reported that patient with a higher expression of lncRNA *CASC15* has a poor prognosis. And, *CASC15* knockdown can inhibit cell proliferation, cell cycle progression, cell invasion ability, and epithelial‐mesenchymal transition (EMT) signaling pathway. However, no study revealed that the correlation between *CASC15* polymorphisms and cervical cancer susceptibility in the Chinese Han women.

Thus, we investigated the relationship between *CASC15* polymorphisms and cervical cancer risk in the Chinese women. The results provided important insights into lncRNA *CASC15* function in the development of cervical cancer.

2. MATERIALS AND METHODS {#mgg31246-sec-0006}
========================

2.1. Study subjects {#mgg31246-sec-0007}
-------------------

A total of 494 cases, newly diagnosed and histologically validated cervical cancer patients, were recruited from Shaanxi Provincial Cancer Hospital in the current study. Patients who have history of gynecologic diseases were excluded from our research. About 504 age and gender‐matched unrelated controls were randomly recruited from the health care in the same hospital during the same time. The following are the exclusion criteria of controls: no gynecological neoplasm, no endometriosis, no other history of solid cancers, and no immune disorders. In addition, demographic and clinical factors, including age, histological types, tumor stage, carcinoembryonic antigen (CEA), serum ferritin (SF), tumor necrosis factor (TNF), sugar antigen (CA), alpha fetoprotein (AFP), and human epididymis protein (HE), were collected. The present study was approved by the clinical ethical committee of the Shaanxi Provincial Cancer Hospital. In addition, the detail researches of this study and the written informed were also signed.

2.2. DNA extraction and genotyping {#mgg31246-sec-0008}
----------------------------------

Peripheral blood samples (5 ml) were obtained from each individual. DNA was isolated from the blood samples by GoldMag DNA purification kit (GoldMag) following the manufacturer\'s instructions. Subsequently, NanoDrop 2000 platform (Thermo Fisher Scientific) was performed to evaluate DNA purity and concentration. Based on the minor allele frequency (MAF) \> 5% and Hardy--Weinberg equilibrium (HWE) \> 0.001%, *CASC15* SNPs were selected in the global population from the 1,000 Genomes Project data (<http://www.internationalgenome.org/>). When *r* ^2^ (the measure value of LD) \> 0.8, the SNP can represent all the polymorphisms in a block. Ultimately, six SNPs including rs1555529 (NC_000006.11:g.21691704A\>G), rs7740084 (NC_000006.11:g.21727531G\>A), rs1928168 (NC_000006.11:g.22017738T\>C), rs12212674 (NC_000006.12:g.22086845T\>A), rs4712653 (NC_000006.11:g.22125964T\>C), and rs9393266 (NC_000006.11:g.22220860C\>T) were finally selected in the present study. Furthermore, the Agena Bioscience Assay Design Suite V2.0 software and the MassARRAY iPLEX platform (Agena Bioscience) designed the amplification and extension primers and conducted the SNPs\' genotyping. In the end, all data were performed by Agena Bioscience TYPER version 4.0 software.

2.3. Statistical analysis {#mgg31246-sec-0009}
-------------------------

Statistical analyses were performed by SPSS 20.0 software. The demographics and genotype frequencies were assessed by χ^2^ tests among all individuals. We applied χ^2^ test to evaluate if the candidate SNPs deviated from Hardy--Weinberg equilibrium. The relationship between *CASC15* polymorphisms and the risk of cervical cancer was assesses through odds ratio (ORs) and 95% confidence interval (CI). We also detected the potential interaction between selected SNPs and cervical cancer risk using the MDR software package. All *p*‐values were two‐tailed and *p* \< .05 was statistically significant.

3. RESULTS {#mgg31246-sec-0010}
==========

3.1. Characteristics of study individuals {#mgg31246-sec-0011}
-----------------------------------------

All of 494 cervical cancer cases and 504 unrelated controls were involved in the research. The detail characteristics of the individuals are listed in Table [1](#mgg31246-tbl-0001){ref-type="table"}. We found that the mean age of cases and controls were 51.65 ± 9.84 years and 51.37 ± 9.66 years, respectively. No difference between cervical cancer cases and healthy controls in age was observed (*p* = .645).

###### 

Characteristics of cases and controls

+------------------------+--------------+--------------+-----------+
| Variables              | Cases        | Controls     | *p‐*value |
|                        |              |              |           |
|                        | (*n* = 494)  | (*n* = 504)  |           |
+========================+==============+==============+===========+
| Age, year (*M* ± *SD*) | 51.65 ± 9.84 | 51.37 ± 9.66 | 0.645     |
+------------------------+--------------+--------------+-----------+
| ≤51                    | 242 (48.99%) | 251 (49.80%) |           |
+------------------------+--------------+--------------+-----------+
| \>51                   | 252 (51.01%) | 253 (50.20%) |           |
+------------------------+--------------+--------------+-----------+
| Histological types     |              |              |           |
+------------------------+--------------+--------------+-----------+
| Squamous carcinoma     | 161 (32.59%) |              |           |
+------------------------+--------------+--------------+-----------+
| Adenocarcinoma         | 13 (2.63%)   |              |           |
+------------------------+--------------+--------------+-----------+
| Information loss       | 320 (64.78%) |              |           |
+------------------------+--------------+--------------+-----------+
| Tumor stage            |              |              |           |
+------------------------+--------------+--------------+-----------+
| Ⅲ--Ⅳ                   | 10 (2.02%)   |              |           |
+------------------------+--------------+--------------+-----------+
| Ⅰ--Ⅱ                   | 52 (10.53%)  |              |           |
+------------------------+--------------+--------------+-----------+
| Information loss       | 432 (87.45%) |              |           |
+------------------------+--------------+--------------+-----------+

*p* values were calculated from χ^2^ test. *p* \< .05 indicates statistical significance.

Abbreviation: *SD*, standard deviation.
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3.2. *CASC15* polymorphisms and cervical cancer risk {#mgg31246-sec-0012}
----------------------------------------------------

The detail information (such as the position, MAF, and HWE *p* value) of the candidate SNPs in participants is summarized in Table [2](#mgg31246-tbl-0002){ref-type="table"}. The results confirmed that the genotype frequencies of the selected six SNPs were all in accord with Hardy--Weinberg equilibrium (*p* \> .05).

###### 

Basic characteristics and allele frequencies among *CASC15* SNPs

  SNP          Chr   Allele   MAF    HWE *p‐*value   
  ------------ ----- -------- ------ --------------- ------
  rs1555529    6     A/G      0.36   0.38            .849
  rs7740084    6     G/A      0.44   0.45            .928
  rs1928168    6     C/T      0.20   0.19            .319
  rs12212674   6     A/T      0.15   0.12            .209
  rs4712653    6     T/C      0.27   0.26            .489
  rs9393266    6     T/C      0.48   0.50            .422

Hardy--Weinberg equilibrium; The GenBank reference of the *CASC15* was NC_000006.12. *p* values were calculated with two‐sided χ^2^.

Abbreviation: MAF, minor allele frequency; SNP, single nucleotide polymorphism.

John Wiley & Sons, Ltd

The allele and genotype frequencies distribution were analyzed by χ^2^ tests and odds ratios (ORs) to assess the correlation with cervical cancer risk. All results are displayed in Table [3](#mgg31246-tbl-0003){ref-type="table"}. We validated that the "A" allele of rs12212674 increased the risk of cervical cancer (OR = 1.31, 95% CI = 1.01--1.69, *p* = .041), when compared with the "T" allele. In addition, the relationship between *CASC15* polymorphisms and cervical cancer sensibility was examined in four genetic models. We observed that rs12212674 of *CASC15* improved cervical cancer risk (OR = 1.32, 95% CI = 1.02--1.72, *p* = .037) in the log‐additive model. However, no significant interaction was confirmed among the remaining SNPs of *CASC15* polymorphisms and the risk of cervical cancer.

###### 

The association between six SNPs within the *CASC15* and the risk of cervical cancer

  SNP            Model     Genotype   Cases                   Controls                OR (95% CI)   *p‐*value
  -------------- --------- ---------- ----------------------- ----------------------- ------------- -----------
  rs1555529      Allele    G          637                     630                     1              
  A              351       378        0.92 (0.77--1.10)       .360                                  
  Co‐dominant    G/G       212        198                     1                                     
  G/A            213       234        0.85 (0.65--1.11)       .227                                  
  A/A            69        72         0.89 (0.61--1.31)       .564                                  
  Dominant       G/G       212        198                     1                                     
  G/A‐A/A        282       306        0.86 (0.67--1.11)       .236                                  
  Recessive      G/G‐G/A   425        432                     1                                     
  A/A            69        72         0.97 (0.68--1.39)       .885                                  
  Log‐additive   ---       ---        ---                     0.92 (0.77--1.10)       .361          
  rs7740084      Allele    A          556                     549                     1              
  G              448       439        0.99 (0.83--1.18)       .933                                  
  Co‐dominant    A/A       158        153                     1                                     
  A/G            233       250        0.90 (0.68--1.20)       .483                                  
  G/G            103       99         1.01 (0.71--1.43)       .976                                  
  Dominant       A/A       158        153                     1                                     
  G/A‐G/G        336       349        0.93 (0.71--1.22)       .607                                  
  Recessive      A/A‐G/A   391        403                     1                                     
  G/G            103       99         1.07 (0.79--1.46)       .669                                  
  Log‐additive   ---       ---        ---                     0.99 (0.83--1.18)       .925          
  rs1928168      Allele    T          794                     810                     1              
  C              194       196        1.01 (0.81--1.26)       .932                                  
  Co‐dominant    T/T       321        322                     1                                     
  T/C            152       166        0.92 (0.70--1.20)       .532                                  
  C/C            21        15         1.40 (0.71--2.76)       .336                                  
  Dominant       T/T       321        322                     1                                     
  T/C‐C/C        173       181        0.96 (0.74--1.24)       .742                                  
  Recessive      T/T‐T/C   473        488                     1                                     
  C/C            21        15         1.44 (0.73--2.82)       .292                                  
  Log‐additive   ---       ---        ---                     1.01 (0.81--1.26)       .943          
  rs12212674     Allele    T          887                     835                     1              
  A              121       149        **1.31 (1.01--1.69)**   **.041**                              
  Co‐dominant    T/T       353        387                     1                                     
  T/A            129       113        1.25 (0.94--1.68)       .128                                  
  A/A            10        4          2.74 (0.85--8.81)       .091                                  
  Dominant       T/T       353        387                     1                                     
  T/A‐A/A        139       117        1.31 (0.98--1.74)       .068                                  
  Recessive      T/T‐T/A   482        500                     1                                     
  A/A            10        4          2.59 (0.81--8.32)       .110                                  
  Log‐additive   ---       ---        ---                     **1.32 (1.02--1.72)**   **.037**      
  rs4712653      Allele    C          718                     741                     1              
  T              270       263        1.06 (0.87--1.29)       .568                                  
  Co‐dominant    C/C       260        270                     1                                     
  C/T            198       201        1.02 (0.79--1.33)       .865                                  
  T/T            36        31         1.21 (0.72--2.01)       .472                                  
  Dominant       C/C       260        270                     1                                     
  C/T‐T/T        234       232        1.05 (0.82--1.34)       .717                                  
  Recessive      C/C‐C/T   458        471                     1                                     
  T/T            36        31         1.19 (0.73--1.96)       .485                                  
  Log‐additive   ---       ---        ---                     1.06 (0.87--1.30)       .565          
  rs9393266      Allele    C          506                     504                     1              
  T              496       472        0.96 (0.80--1.14)       .612                                  
  Co‐dominant    C/C       122        123                     1                                     
  C/T            260       260        1.01 (0.75--1.37)       .943                                  
  T/T            106       118        0.91 (0.63--1.30)       .599                                  
  Dominant       C/C       122        123                     1                                     
  C/T‐T/T        366       378        0.98 (0.73--1.31)       .884                                  
  Recessive      C/C‐C/T   382        383                     1                                     
  T/T            106       118        0.90 (0.67--1.21)       .490                                  
  Log‐additive   ---       ---        ---                     0.95 (0.80--1.14)       .609          

The GenBank reference of the *CASC15* was NC_000006.12. Bold type indicates statistical significance (*p* \< .05).

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.
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3.3. Stratified analysis of *CASC15* polymorphisms and cervical cancer risk {#mgg31246-sec-0013}
---------------------------------------------------------------------------

To control potential confounders, the participants were stratified by age. We demonstrated that rs4712653 "TT" genotype was associated with an increased risk of cervical cancer in aged ≤51 population (co‐dominant: OR = 2.08, 95% CI = 1.02--4.25, *p* = .044; recessive: OR = 2.11, 95% CI = 1.05--4.24, *p* = .036, respectively). In terms of subjects with age \>51 years, there was no statistically significant association between the candidate SNPs of *CASC15* polymorphisms and cervical cancer risk (*p* \> .05). The results are shown in Table [4](#mgg31246-tbl-0004){ref-type="table"}.

###### 

The association between the *CASC15* polymorphisms and cervical cancer risk stratified by age

  SNP            Model                   Genotype            ≤51                 \>51                       
  -------------- ----------------------- ------------------- ------------------- ------------------- ------ ---
  rs1555529      Allele                  G                   1                                               
  A              0.96 (0.74--1.25)       .760                0.88 (0.68--1.13)   .321                       
  Co‐dominant    G/G                     1                                                                  
  G/A            0.79 (0.54--1.16)       .223                0.76 (0.44--1.30)   .313                       
  A/A            1.06 (0.62--1.82)       .835                0.91 (0.62--1.33)   .617                       
  Dominant       G/G                     1                                                                  
  G/A‐A/A        0.85 (0.59--1.21)       .369                0.87 (0.61--1.25)   .447                       
  Recessive      G/G‐G/A                 1                                                                  
  A/A            1.19 (0.72--1.98)       .496                0.80 (0.48--1.32)   .375                       
  Log‐additive   ---                     0.96 (0.75--1.24)   .767                0.88 (0.68--1.13)   .321   
  rs7740084      Allele                  A                   1                                               
  G              0.97 (0.75--1.24)       .792                1.02 (0.79--1.30)   .899                       
  Co‐dominant    A/A                     1                                                                  
  A/G            1.05 (0.70--1.57)       .818                1.08 (0.66--1.79)   .754                       
  G/G            0.92 (0.55--1.52)       .733                0.78 (0.52--1.17)   .230                       
  Dominant       A/A                     1                                                                  
  G/A--G/G       1.01 (0.69--1.47)       .970                0.86 (0.59--1.26)   .439                       
  Recessive      A/A‐G/A                 1                                                                  
  G/G            0.89 (0.57--1.39)       .612                1.27 (0.82--1.95)   .281                       
  Log‐additive   ---                     0.97 (0.76--1.24)   .797                1.02 (0.79--1.30)   .901   
  rs1928168      Allele                  T                   1                                               
  C              0.93 (0.68--1.28)       .657                1.09 (0.80--1.49)   .580                       
  Co‐dominant    T/T                     1                                                                  
  T/C            0.89 (0.61--1.31)       .560                1.84 (0.72--4.74)   .206                       
  C/C            1.00 (0.37--2.73)       1.000               0.94 (0.64--1.38)   .754                       
  Dominant       T/T                     1                                                                  
  T/C--C/C       0.90 (0.62--1.31)       .585                1.01 (0.70--1.46)   .951                       
  Recessive      T/T--T/C                1                                                                  
  C/C            1.04 (0.38--2.81)       .941                1.88 (0.74--4.80)   .187                       
  Log‐additive   ---                     0.93 (0.67--1.28)   .651                1.09 (0.80--1.48)   .606   
  rs12212674     Allele                  T                   1                                               
  A              1.19 (0.83--1.71)       .335                1.45 (1.00--2.10)   .051                       
  Co‐dominant    T/T                     1                                                                  
  T/A            1.08 (0.72--1.61)       .722                1.85 (0.44--7.85)   .405                       
  A/A            5.4 (0.62--46.76)       .126                1.47 (0.97--2.25)   .072                       
  Dominant       T/T                     1                                                                  
  T/A-- A/A      1.14 (0.77--1.70)       .513                1.50 (0.99--2.26)   .055                       
  Recessive      T/T -- T/A              1                                                                  
  A/A            5.29 (0.61--45.71)      .130                1.69 (0.40--7.15)   .477                       
  Log‐additive   ---                     1.21 (0.83--1.75)   .319                1.45 (0.99--2.11)   .054   
  rs4712653      Allele                  C                   1                                               
  T              1.21 (0.91--1.60)       .188                0.93 (0.70--1.23)   .618                       
  Co‐dominant    C/C                     1                                                                  
  C/T            0.97 (0.67--1.41)       .867                0.61 (0.28--1.34)   .218                       
  T/T            **2.08 (1.02--4.25)**   **.044**            1.08 (0.75--1.55)   .697                       
  Dominant       C/C                     1                                                                  
  C/T‐T/T        1.10 (0.77--1.57)       .608                1.00 (0.71--1.43)   .980                       
  Recessive      C/C‐C/T                 1                                                                  
  T/T            **2.11 (1.05--4.24)**   **.036**            0.59 (0.27--1.28)   .181                       
  Log‐additive   ---                     1.20 (0.91--1.59)   .195                0.93 (0.69--1.24)   .616   
  rs9393266      Allele                  C                   1                                               
  T              1.08 (0.84--1.38)       .574                1.17 (0.92--1.51)   .204                       
  Co‐dominant    C/C                     1                                                                  
  C/T            1.37 (0.89--2.12)       .157                1.38 (0.83--2.28)   .212                       
  T/T            1.16 (0.68--1.96)       .585                1.04 (0.67--1.61)   .861                       
  Dominant       C/C                     1                                                                  
  C/T‐T/T        1.31 (0.86--1.98)       .210                1.14 (0.75--1.73)   .532                       
  Recessive      C/C‐C/T                 1                                                                  
  T/T            0.93 (0.61--1.43)       .741                1.34 (0.90--2.01)   .154                       
  Log‐additive   ---                     1.08 (0.83--1.41)   .555                1.18 (0.91--1.52)   .205   

The GenBank reference of the *CASC15* was NC_000006.12. Bold type indicates statistical significance (*p* \< .05).

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.
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### 3.3.1. SNP--SNP interaction and cervical cancer risk {#mgg31246-sec-0014}

MDR analysis is summarized in Table [5](#mgg31246-tbl-0005){ref-type="table"}. The interaction information analysis showed that the interaction between rs7740084, rs1555529, and rs12212674 had a certain effect on the progress of cervical cancer. The combination of high‐risk and low‐risk genotypes was determined according to the threshold, and we can see that the TT genotype of rs12212674, AA genotype of rs1555529, and AA genotype of rs7740084 had a higher risk of cervical cancer. And, the testing accuracy and cross‐validation consistency of the two locus model (rs7740084 and rs1555529) and the three locus model (rs7740084, rs1555529, and rs12212674) was 54.39%, 4/10 and 56.70%, 4/10, respectively, which was significant.

###### 

Predication of cervical cancer risk factors in MDR analysis

  Best model                         Training accuracy (%)   Testing accuracy (%)   Cross‐validation consistency   χ^2^     *p*
  ---------------------------------- ----------------------- ---------------------- ------------------------------ -------- ------------
  rs12212674                         52.72                   49.03                  7/10                           3.695    .055
  rs1555529\|rs7740084               54.39                   44.66                  4/10                           6.344    **.012**
  rs7740084\|rs1555529\|rs12212674   56.70                   46.95                  4/10                           16.447   **\<.000**

*p*‐values were calculated by Pearson χ^2^ test. Bold type indicates statistical significance (*p* \< .05).

Abbreviation: MDR, multifactor dimensionality reduction.
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4. DISCUSSION {#mgg31246-sec-0015}
=============

Cervical cancer is a common frequent cancer among women. It was reported that cervical cancer has a high mortality worldwide (McGuire, [2016](#mgg31246-bib-0015){ref-type="ref"}). Recent evidences indicated that genetic factors played a crucial role in the development of cervical cancer (Liu et al., [2019](#mgg31246-bib-0013){ref-type="ref"}). The case‐control study indicated that rs12212674 of *CASC15* polymorphisms was significantly associated with an increased risk of cervical cancer (*p* = .041). The "TT" genotype of rs4712653 was related to improved cervical cancer risk in aged ≤51 populations (*p* = .036).

Growing researches have confirmed that lncRNAs may have an effect on various malignant tumors, including cervical cancer, through regulating cell differentiation, proliferation, apoptosis, migration, and invasion (Camacho, Choudhari, & Gadad, [2018](#mgg31246-bib-0001){ref-type="ref"}; Tang et al., [2017](#mgg31246-bib-0019){ref-type="ref"}). Gao et al suggested that lncRNA *PANDAR* (OMIM\# 617179) was significantly associated with cervical cancer, and upregulation of lncRNA *PANDAR* can promote cervical cancer cell proliferation (Huang, Xie, Ma, Zhao, & Gao, [2017](#mgg31246-bib-0010){ref-type="ref"}). Recent study has shown that lncRNA *HOTAIR* (OMIM\# 611400) was heightened in cervical cancer tissues and correlated with poor prognosis of cervical cancer patients (Li, Wang, Yu, Dong, & Qiu, [2015](#mgg31246-bib-0012){ref-type="ref"}). In addition, a study including 1,209 patients and 1,348 healthy controls also demonstrated that rs7958904 of *HOTAIR* might affect cervical cancer susceptibility by modulation of cervical cancer cell proliferation (Jin et al., [2017](#mgg31246-bib-0011){ref-type="ref"}). Wang et al suggested that rs11655237 (NC_000017.10:g.70400166C\>T) of LINC00673 (OMIM\# 617079) polymorphism was correlated with cervical cancer risk among Chinese population (Wang & Luo, [2018](#mgg31246-bib-0020){ref-type="ref"}). Moreover, numerous lncRNAs are abnormally expressed in cervical cancer (Peng, Yuan, Jiang, Tang, & Li, [2016](#mgg31246-bib-0016){ref-type="ref"}). To date, no studies have reported the correlation between lncRNA *CASC15* polymorphisms and cervical cancer susceptibility in Chinese females.

Several studies have indicated that *CASC15* expression was associated with different human diseases, including neuroblastoma (Russell et al., [2015](#mgg31246-bib-0017){ref-type="ref"}), hepatocellular carcinoma (He, Zhang, et al., [2017](#mgg31246-bib-0009){ref-type="ref"}), acute leukemia (Fernando et al., [2017](#mgg31246-bib-0003){ref-type="ref"}), and gastric cancer (Yao et al., [2017](#mgg31246-bib-0022){ref-type="ref"}; Yuan et al., [2012](#mgg31246-bib-0024){ref-type="ref"}). Two genome‐wide association studies (GWASs) have verified that *CASC15* rs4712653 T\>C was correlated with a decreased risk of neuroblastoma in Chinese children (He et al., [2016](#mgg31246-bib-0007){ref-type="ref"}; He, Zou, et al., [2017](#mgg31246-bib-0008){ref-type="ref"}). To our best knowledge, we firstly demonstrated that *CASC15* polymorphisms were interaction with cervical cancer susceptibility in Chinese women. We observed that *CASC15* rs4712653 "TT" genotype was associated with the risk of cervical cancer in aged ≤51 people (*p* = .036).

In summary, the results revealed the role of *CASC15* polymorphisms in cervical cancer sensibility among Chinese women. Besides, detail molecular mechanism studies to further explore the role of *CASC15* variants in increasing cervical cancer risk were necessary to be performed.
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